Pantoprazole Zentiva Pharma (Pantoprazole Sodium Sesquihydrate)

Pantoprazole, the active ingredient in Pantoprazole Zentiva Pharma, is a proton pump inhibitor presented as oral tablets for oral use. It reduces gastric acid secretion and is employed in the management of acid‑related gastrointestinal disorders such as gastro‑oesophageal reflux disease and ulcer‑related conditions.

GNH USA supplies Pantoprazole Zentiva Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Pantoprazole is indicated for several acid‑related gastrointestinal conditions where suppression of gastric acid is required.

- Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and regurgitation by maintaining higher gastric pH. - Erosive esophagitis: promotes healing of mucosal lesions caused by acid exposure. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with gastrin‑producing tumors. - Prevention of NSAID‑induced gastric ulcers: reduces risk of ulcer formation in patients receiving non‑steroidal anti‑inflammatory drugs.

Pantoprazole may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Severe allergic reactions (e.g., Stevens‑Johnson syndrome, anaphylaxis) - Clostridioides difficile‑associated diarrhea - Low serum magnesium (hypomagnesemia) - Elevated liver enzymes - Interstitial nephritis - Bone fractures with long‑term use

Before initiating pantoprazole therapy, clinicians should evaluate patient‑specific factors and follow safety recommendations. - Renal function: assess and adjust use in severe renal impairment. - Hepatic impairment: use caution and monitor liver function tests. - Magnesium levels: monitor during prolonged therapy to detect hypomagnesemia. - Osteoporosis risk: consider bone health in patients requiring long‑term treatment. - Concomitant drugs: review medications that may alter gastric pH or interact with pantoprazole. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Pantoprazole can affect the pharmacokinetics of several medicines; awareness of key interactions helps optimize therapy.

Major Interactions (Avoid): - Rilpivirine: reduced absorption leading to loss of antiviral efficacy. - Atazanavir: decreased plasma concentrations compromising HIV treatment. - Clopidogrel: impaired activation reducing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation. - Digoxin: higher serum levels may occur; check concentrations. - Ketoconazole: reduced absorption; consider alternative antifungal or dosing adjustment.